Ingmar Hoerr, PhD, MBA, Co-Founder / Chairman of the Supervisory Board founded the biopharmaceutical company CureVac in the year 2000 in Tuebingen. His entrepreneurship was motivated by a surprising discovery during his doctoral research. Experiments conducted for his research showed that the mRNA molecule class can be injected into tissue directly and is capable of expressing genes into proteins effectively as well as generating a strong specific immune response, contrary to what had previously been believed.
From this key discovery, in his role as CEO he built up a company that was the first ever to treat a human subject with an mRNA drug and that is now a leading German “unicorn” in the research and development of mRNA-based drugs. Since its inception, CureVac has received approximately $420 million (€400 million) in equity investments.
Ingmar Hoerr received his PhD from the University of Tübingen and his MBA from Danube University, Krems, Austria. He currently advises the European Commission as member of the High Level Group of Innovators in developing a European Innovation Council and is juror of the founder prize Weconomy. Since March, he serves on the „Founding Board of Agency of Disruptive Innovations“.